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Angiopoietin-like protein 4 (ANGPTL4/FIAF) has been proposed as a circulating mediator between the gut microbiota and fat
storage. Here, we show that transcription and secretion of ANGPTL4 in human T84 and HT29 colon adenocarcinoma cells is
highly induced by physiological concentrations of short-chain fatty acids (SCFA). SCFA induce ANGPTL4 by activating the nu-
clear receptor peroxisome proliferator activated receptor  (PPAR), as demonstrated using PPAR antagonist, PPAR knock-
down, and transactivation assays, which show activation of PPAR but not PPAR and PPAR by SCFA. At concentrations re-
quired for PPAR activation and ANGPTL4 induction in colon adenocarcinoma cells, SCFA do not stimulate PPAR in mouse
3T3-L1 and human SGBS adipocytes, suggesting that SCFA act as selective PPARmodulators (SPPARM), which is supported by
coactivator peptide recruitment assay and structural modeling. Consistent with the notion that fermentation leads to PPAR acti-
vation in vivo, feeding mice a diet rich in inulin induced PPAR target genes and pathways in the colon. We conclude that (i)
SCFA potently stimulate ANGPTL4 synthesis in human colon adenocarcinoma cells and (ii) SCFA transactivate and bind to
PPAR. Our data point to activation of PPARs as a novel mechanism of gene regulation by SCFA in the colon, in addition to
other mechanisms of action of SCFA.
In the last decade, interest in the role of the intestinal micro-biota has grown exponentially. The functional role of the gut
microbiota has been studied mainly in relation to intestinal
health and immune function. However, there are growing
speculations that the gut microbiota also influence other dis-
eases, including type 1 diabetes, autism, and obesity, and im-
pact more distant organs (1). Those notions have spurred the
search for circulating factors that communicate between the
intestinal microbiota and other parts of the body. One factor
that was found to be strongly downregulated in intestine upon
colonization of the gut of germ-free mice with microbiota and
that appears to be important for microbiota-induced deposi-
tion of triglycerides in adipocytes is angiopoietin-like 4
(ANGPTL4), also referred to as FIAF (fasting-induced adipose
factor) (2, 3). ANGPTL4 is secreted by a variety of tissues, includ-
ing adipose tissue, liver, skeletal muscle, and intestine (4). It is
released as a 50-kDa prohormone that is subsequently cleaved
into N- and C-terminal fragments. The N-terminal fragment of
ANGPTL4 blocks activity of the enzyme lipoprotein lipase (LPL),
which catalyzes uptake of circulating lipids into tissues (5). Ac-
cordingly, ANGPTL4 overexpression raises circulating triglycer-
ide levels (6–10). In cardiomyocytes and macrophages, induction
of ANGPTL4 by fatty acids and subsequent inhibition of LPL is
part of a feedback mechanism aimed at preventing cellular lipid
overload and thus reducing lipotoxicity and inflammation
(11, 12).
Expression of ANGPTL4 is under transcriptional control of
peroxisome proliferator-activated receptors (PPARs). Indeed,
ANGPTL4 was originally cloned as a target gene of PPAR and
PPAR (13, 14). Depending on the specific tissue, ANGPTL4
mRNA levels are governed primarily by PPAR (liver and small
intestine) (13, 15), PPAR (skeletal muscle, heart, and macro-
phages) (11, 12, 16), or PPAR (adipocytes) (13, 14). In addition
to the tissues mentioned above, ANGPTL4 is also expressed in
human colon (17) (http://biogps.org/), but little is known about
the factors regulating ANGPTL4 mRNA expression and protein
secretion in this tissue. PPAR is highly expressed in human
colonocytes, followed by PPAR and, to a lesser extent, PPAR,
suggesting that PPARs are important regulators of ANGPTL4 ex-
pression (18). A similar expression profile is found in mouse
colonocytes (19). Considering the status of ANGPTL4 as a puta-
tive mediator between the gut microbiota and adipose tissue, we
were interested in identifying the microbiota-related factors that
influence ANGPTL4 production in the colon. Previously,ANGPTL4
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expression in the human colon cell line HT29 was found to be
stimulated by heat-stable factors secreted by the probiotic bacteria
Lactobacillus sp. strain F19 (20). We hypothesized that these fac-
tors corresponded to short-chain fatty acids (SCFA), which are
compounds formed by intestinal microbial activity. Accordingly,
we studied the regulation of ANGPTL4 by SCFA.
MATERIALS AND METHODS
Animal experiments.Male C57BL/6J mice were purchased from Charles
River Laboratories. Theywere housed in pairs on a 12-h light/dark cycle at
21°C with free access to feed and water throughout the experimental pe-
riod. For 2 weeks before the start of the interventions, mice were fed a
standard semisynthetic low-fat diet based on D12450B (Research Diets
Inc., New Brunswick, NJ), with modified content of sucrose and corn
starch (16.4 and 40.5%, wt/wt, respectively). In the first experiment, 12-
week-oldmice were mildly sedated with isoflurane at 9:00 a.m.Mice were
kept under sedation and received either an 80-l rectal infusion of saline
(n  4) or saline containing 100 mM sodium propionate (n  4). Both
solutions had a pH of 6.5. The solutions were administered by inserting a
gel-loading tip 3 cm into the rectum and slowly pushing the solution out
of the tip. The infusions were administered on 6 consecutive days. Four
hours after the rectal infusion on day 6, mice were anesthetized with
isoflurane and subsequently sacrificed by cervical dislocation. The colon
was excised, and adhering fat was carefully removed. The epithelial lining
of the colon was scraped and immediately frozen in liquid nitrogen to be
stored at80°C for subsequent RNA isolation. In the second experiment,
mice were stratified according to their body weight and allocated to the
control diet group (n 5; low-fat diet as described above) or inulin diet
group (n  6; low-fat diet with 10% [wt/wt] corn starch replaced by
inulin). After 10 days of dietary intervention, mice were fasted overnight
and provided with 1 g of experimental diet. After 4 h, mice were anesthe-
tized using isoflurane and sacrificed by cervical dislocation. Colon was
removed, and luminal content and mucosal scrapings were collected,
snap-frozen in liquid nitrogen, and stored at80°C (scrapings) or20°C
(content). Luminal content was used for SCFAmeasurement by gas chro-
matography. Mucosal scrapings were used for RNA isolation. The exper-
iments were authorized by the Local Committee for Care and Use of
Laboratory Animals at Wageningen University.
SCFA measurement. SCFA concentrations were measured in the lu-
minal content of different parts of the gastrointestinal (GI) tract of
C57BL/6 mice fed a low-fat diet. After sacrifice, luminal content was col-
lected in tubes containing phosphoric (H3PO4) and isocaproic acid, after
which the tubeswere thoroughlymixed and stored at20°C. For analysis,
samples were thawed, mixed on a vortex, and centrifuged at 14,000 rpm
for 5 min. The supernatant was collected and SCFA concentrations were
determined by gas chromatography (Fisons HRGC Mega 2; CE Instru-
ments,Milan, Italy) at 190°Cusing a glass columnfittedwithChromosorb
101. The carrier gas was N2 saturated withmethanoic acid, and isocaproic
acid was used as an internal standard.
Cell culture. T84 and HT29 human colonic carcinoma epithelial cells
were cultured inDulbecco’smodified Eaglemedium (DMEM) orDMEM
containing Ham’s F-12medium (DMEMF-12) (Lonza, the Netherlands)
containing 5 or 10% fetal calf serum (FCS), respectively, and 1% penicil-
lin-streptomycin at 37°C in a humidified incubator under 95%air and 5%
CO2. Cells were grown until 80 to 90% confluence and treated for the
indicated time periods with sodium acetate, sodium propionate, and so-
dium butyrate from a stock in phosphate-buffered saline (PBS) to a final
concentration of 1 or 8 mM. Alternatively, cells were treated with syn-
thetic agonists for PPAR (Wy14643; 5M), PPAR (GW501516; 1M),
PPAR (rosiglitazone; 1 M), synthetic PPAR antagonist GW9662 (5
M), or trichostatin A (100 nM) from a stock in dimethylsulfoxide
(DMSO). In one experiment, cells were preincubated with -amanitin
(10g/ml) from a stock in water for 1 h, followed by 24 h of coincubation
with butyrate at 1 mM. After the indicated time points, medium was
collected and used for analysis of ANGPTL4 by enzyme-linked immu-
nosorbent assay (ELISA), and/or cells were harvested for subsequent RNA
isolation.
siRNA transfection. Silencing of the PPAR gene in T84 cells was
done using ON-TARGETplus SMARTpool for human PPAR (Thermo
Scientific Dharmacon, Etten-Leur, the Netherlands), representing a mix-
ture of four short interfering RNAs (siRNAs): CAAAUCACCAUUCGU
UAUC, GACAUGAAUUCCUUAAUGA, GAUAUCAAGCCCUUCA
CUA, and GACAGCGACUUGGCAAUAU. As a control, we used an
ON-TARGETplus nontargeting pool (Thermo Scientific Dharmacon).
Transfection was done according to the manufacturer’s protocol using
DharmaFECT 1 transfection reagent. The cells were transfected with
100 nM siRNA and incubated for 48 h, followed by treatment with bu-
tyrate (1 mM) for a period of 24 h. Thereafter, medium was collected for
ANGPTL4 protein analysis by ELISA and the cells were used for RNA
isolation and subsequent quantitative PCR (qPCR).
PPAR ChIP. T84 cells were grown in 10-cm plates to a density of
approximately 5 million cells/dish and treated with butyrate (8 mM) or
rosiglitazone (1M). After 1 h,mediumwas removed and cells were fixed
in 1% formaldehyde in PBS. After 10 min, cross-linking was stopped by
the addition of glycine to a final concentration of 0.125 M. The cells were
washed three times with ice-cold PBS and resuspended in 0.3 ml of lysis
buffer (0.1% SDS, 1% Triton X-100, 0.15 M NaCl, 1 mM EDTA, 20 mM
Tris, pH 8.0). The lysate was frozen at 80°C until further analysis.
Chromatin immunoprecipitation (ChIP) was carried out as described by
Siersbæk et al. (21), with the exceptions that disuccinimidyl glutarate was
not used for cross-linking and sonicationwas performed in 2 rounds of 10
on/off cycles of 30 s each. The PPAR antibody used was PPAR H100
(sc-7196; Santa Cruz Biotechnologies).
PPAR stable reporter assay. The PPAR CALUX cell line was ob-
tained from BioDetection Systems B.V. (Amsterdam, the Netherlands).
PPAR CALUX cells are based on human osteoblastic (U2-OS) cells
(American Type Culture Collection [ATCC],Manassas, VA) stably trans-
fected with a human PPAR expression plasmid and a luciferase reporter
construct (22). The cells were cultured as described previously in a 1:1
mixture of DMEM and Ham’s F-12 medium (Invitrogen, Breda, the
Netherlands) supplemented with 7.5% fetal bovine serum (FBS) (Invit-
rogen), 1% nonessential amino acids (Invitrogen), and penicillin-strep-
tomycin (Invitrogen) to final concentrations of 10 U/ml and 10 g/ml,
respectively (22, 23). Once per month 200 g/ml G418-disulfate was
added to the culture medium.
The PPARCALUX assay was performed as described previously (22,
24). In short, for the exposure experiments, PPAR-CALUX cells were
plated in the 96-well plates with phenolred-free 1:1 mixture of DMEM
and Ham’s F-12 medium supplemented with 5% dextran-coated char-
coal-stripped FBS (Invitrogen) at a volume of 200 l per well. The next
day,mediumwas refreshed and cells were incubated in triplicates with test
compounds added to the culture medium. After 24 h, the cells were
checked visually for cytotoxicity, the medium was removed, and the cells
were lysed in luciferase cell culture lysis reagent (Promega, Leiden, the
Netherlands). Luciferase activity was measured in cellular extracts using a
Synergy HTmultidetectionmicroplate reader (BioTek Instruments Inc.).
For each test compound at last two independent experiments were per-
formed.
GAL4-PPAR stable reporter assay. The GAL4-PPAR stable reporter
assay was carried out in HeLa cells stably expressing a chimeric protein
containing the ligand binding domain (LBD) of human PPAR, PPAR,
or PPAR fused to the yeast transactivator GAL4 DNA binding domain
(DBD) and a luciferase reporter gene driven by a pentamer of the GAL4
recognition sequence in front of a -globin promoter. The cells were
seeded in 96-well plates and incubated the following day with tested com-
pounds for 24 h. At the end of the incubation, the luciferase activity was
measured using a BMGLUMIstar Galaxy luminometer. Results expressed
as relative light units (RLU) were obtained from experiments performed
in triplicate. Rosiglitazone, GW7647, and L165041 (all at 1M)were used
as positive controls for activation of PPAR, PPAR, and PPAR, respec-
Alex et al.
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tively. The measurements were performed as a commercial service by
Tebu-bio Laboratories (Le Perray-en-Yvelines, France).
ANGPTL4 ELISA.ANGPTL4 levels in the mediumwere measured by
ELISA as detailed previously (17). Briefly, 96-well plates were coated with
anti-human ANGPTL4 polyclonal goat IgG antibody (AF3485; R&D Sys-
tems) and incubated overnight at 4°C. Plates were washed extensively
between each step. After blocking, 100 l of medium of cells was applied,
followed by 2 h of incubation at room temperature. A standard curve
was prepared using recombinant human ANGPTL4 (3485-AN; R&D
Systems) at 0.3 to 2.1 ng/well. One hundred microliters of diluted biotin-
ylated anti-human ANGPTL4 polyclonal goat IgG antibody (BAF3485;
R&D Systems) then was added for 2 h, followed by addition of streptavi-
din-conjugated horseradish peroxidase for 20 min and tetramethyl ben-
zidine substrate reagent for 6 min. The reaction was stopped by the addi-
tion of 50l of 10%H2SO4, and the absorbance wasmeasured at 450 nm.
Cofactor recruitment assay. Nuclear receptor PamChip arrays
(PamGene, s’Hertogenbosch, the Netherlands) were used as described
previously (25). Upon binding a ligand, PPARs undergo a conformational
change that promotes the formation of a cofactor binding pocket, subse-
quently allowing interaction with the so-called LXXLLmotif within some
coregulators. The PamChip arrays consist of 53 peptides encompassing
the LXXLL motifs of 21 different coregulator proteins. The sequences are
provided as supplementary data in Koppen et al. (25). Briefly, the arrays
were incubatedwith glutathione S-transferase-tagged PPAR LBD (Invit-
rogen, Breda, the Netherlands) in the presence and absence of the ligands,
i.e., sodium acetate, sodium propionate, sodium butyrate (each at 40 mM),
and rosiglitazone (1 M). Quantification of the interaction between
PPAR and coregulators was made using Alexa 488-conjugated anti-glu-
tathione S-transferase rabbit polyclonal antibody (Invitrogen).
Affymetrix GeneChip microarray analysis. Microarray analysis was
performed on T84 cells treated with 0.1 M rosiglitazone or 1 mM bu-
tyrate for 24 h. Total RNAwas prepared usingTRIzol reagent (Invitrogen)
and purified on columns using the RNeasy Minikit (Qiagen, Venlo, the
Netherlands). RNA quality and integrity were verified with the RNA 6000
Nano assay on an Agilent 2100 Bioanalyzer (Agilent Technologies, Am-
sterdam, the Netherlands). Hybridization, washing, and scanning of the
Affymetrix Human Gene 1.1 ST array plate was performed on Affymetrix
GeneTitan. Scans of the Affymetrix arrays were processed using packages
from the Bioconductor project (26). Raw signal intensities were obtained
by robust multiarray (RMA) normalization (27). Probe sets were defined
according to Dai et al. using remapped chip definition file (CDF), version
15, based on data from the Entrez gene database (28).
Microarray analysis of colon of mice fed inulin was carried out as
described above using the Affymetrix Mouse Gene 1.1 ST array plate.
3T3-L1 adipogenesis. 3T3-L1 fibroblasts were amplified in DMEM-
10% FCS and subsequently seeded into six-well plates. Two days after the
cells reached confluence, the medium was changed to DMEM-10% fetal
calf serum containing 0.5 mM 3-isobutyl-1-methylxanthine, 2 g/ml in-
sulin (Actrapid), 0.5Mdexamethasone, and either the short-chain fatty
acids or rosiglitazone (1 M). After 2 days, the medium was changed to
DMEM-10% fetal calf serum containing 2 g/ml insulin and the short-
chain fatty acids or rosiglitazone. Cells were harvested after twomore days
for RNA isolation (day 4). This mild adipogenesis protocol permits as-
sessment of PPAR agonist activity of added compounds (29). Oil red O
staining was performed at day 10 using a standard protocol.
In a second protocol, 2 days after the cell confluence (i.e., day 0), the
mediumwas changed to DMEM-10% fetal calf serum containing 0.5mM
3-isobutyl-1-methylxanthine, 5g/ml insulin, and 1Mdexamethasone.
After 3 days, the medium was changed to DMEM-10% fetal calf serum
containing 5g/ml insulin. Themediumwas subsequently changed every
3 days, and no further insulin was added after 6 days. At day 10, 3T3-L1
adipocytes were treated with rosiglitazone (1 M) and the short-chain
fatty acids (8 mM) for 24 h.
Adipogenesis in SGBS. Human Simpson-Golabi-Behmel syndrome
(SGBS) adipocytes were cultured and grown to confluence in 0F medium
(DMEM–F-12–biotin–panthotenate–penicillin-streptomycin) plus 10%
FCS. One day postconfluence, the medium was changed to Quick-diff
medium, which is 3FC medium (0F medium plus 0.01 mg/ml human
apotransferrin, 2 108 M insulin, 0.1 M cortisol, 0.2 nM T3) with 50
nM dexamethasone, 500 M 3-isobutyl-1-methylxanthine, and 2 M
rosiglitazone or 8 mM SCFA. On day 4, medium was changed to 3FC
medium and changed every 4 days until day 15. Expression of differenti-
ation markers and PPAR targets was determined by qPCR at day 15.
DMSO was used as a control.
RNA isolation and qPCR. RNA was isolated from T84 cells using
RNeasy columns or TRIzol. One g of total RNA was reverse transcribed
with iScript (Bio-Rad, Veenendaal, the Netherlands) or a Fermentas
cDNA synthesis kit according to the instructions from the manufacturer.
cDNA was amplified on a Bio-Rad CFX384 real-time system using Sensi-
mix (Bioline, GC Biotech, Alphen aan de Rijn, the Netherlands). Cyclo-
philin or 36B4 was used as a housekeeping gene. PCR primer sequences
were taken from the PrimerBank and ordered from Eurogentec (Seraing,
Belgium). Primer sequences are presented in Table 1.
Modeling of butyrate binding to PPAR. Formodeling the structure
of the complex betweenPPAR and butyrate,HADDOCKversion 2.1was
used (30). HADDOCK is a highly successful modeling approach that
makes use of structural knowledge when available to drive the docking
procedure. In this case, the X-ray crystal structure of PPAR with bound
decanoic acid (DA; 3U9Q) was used to identify the likely binding site for
short-chain fatty acids such as butyrate (31). The docking was performed
using the web server version ofHADDOCK (32), with the followingmod-
ifications. The high-temperature rigid-body torsion angle dynamics and
the first rigid-body cooling stage were not performed (i.e., the number of
stepswas set to 0), and the second cooling phase of torsion angle dynamics
with flexible side chains at the interface was started with a reduced initial
temperature of 500K instead of the default 1,000K.
All calculations were performed with CNS1.2 (33). Nonbonded inter-
actions were calculated with the OPLS force field using a cutoff of 8.5 Å
(34). The electrostatic potential (Eelec) was calculated by using a shift
function, while a switching function (between 6.5 and 8.5Å) was used to
define the Van der Waals potential (EvdW). The HADDOCK score (in
arbitrary units [AU])was used to rank the generated poses. It is a weighted
sum of intermolecular electrostatic (Eelec), van der Waals (EvdW), des-
olvation (Edesolv), and ambiguous interaction restraint (AIR) energies
with weight factors of 0.2, 1.0, 1.0, and 0.1, respectively.
The ambiguous interaction restraints used to drive the docking of
butyrate to PPAR were derived from the X-ray crystal structure of
PPARwith boundDA (3U9Q), where protein residues near the decanoic
acid were identified as the butyrate binding site. All protein residues
within 3.9 Å of the decanoic acid (residues 278, 281, 282, 285, 289, 323,
356, 360, 363, 449, 469, and 473) were defined as active restraints for the
rigid-body docking phase and as passive restraints for the subsequent
semiflexible refinement stage. The ligand was considered active for both
TABLE 1 List of primers used
Name
Primer sequence
Forward Reverse
m36B4 ATGGGTACAAGCGCGTCCTG GCCTTGACCTTTTCAGTAAG
Fabp4 AAGAAGTGGGAGTGGGCTTT AATCCCCATTTACGCTGATG
Gyk ATCCGCTGGCTAAGAGACAACC TGCACTGGGCTCCCAATAAGG
Slc2a4 GGAAGGAAAAGGGCTATGCTG TGAGGAACCGTCCAAGAATGA
Adipoq GCAGAGATGGCACTCCTGGA CCCTTCAGCTCCTGTCATTCC
Angptl4 GTTTGCAGACTCAGCTCAAGG CCAAGAGGTCTATCTGGCTCTG
ANGPTL4 CACAGCCTGCAGACACAACTC GGAGGCCAAACTGGCTTTGC
PPARG GAGCCCAAGTTTGAGTTTGC CAGGGCTTGTAGCAGGTTGT
PPARA CAGAACAAGGAGGCGGAGGTC TTCAGGTCCAAGTTTGCGAAGC
PPARD TGGCTTTGTCACCCGTGAGT ACAGAATGATGGCCGCAATGAA
PLIN2 ATGGCATCCGTTGCAGTTGAT GATGGTCTTCACACCGTTCTC
UCP2 TGCCCTCCTGAAAGCCAAC CTTGACCACGTCTACAGGGGA
AQP8 GCGAGTGTCCTGGTACGAAC CAGGCACCCGATGAAGATGAA
LGALS1 TCGCCAGCAACCTGAATCTC GCACGAAGCTCTTAGCGTCA
h36B4 CGGGAAGGCTGTGGTGCTG GTGAACACAAAGCCCACATTCC
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docking phases. This strategy effectively pulls the butyrate ligand into the
binding site during rigid-body docking while allowing a thorough explo-
ration of the binding pocket during the refinement stage.With the protein
active-site residues defined as passive during the semiflexible refinement
stage, the ligand is not restrained to any particular orientation or location
within the defined binding site. For comparison, a second docking trial
was performed with active residues for the entire PPAR binding site,
defined as amino acids within 3.9Å of either the partial agonist decanoic
acid (from 3U9Q, residues 278, 281, 282, 285, 289, 323, 356, 360, 363, 449,
469, and 473) or the full agonist-nitrosylated fatty acid (from 3CWD,
residues 285, 286, 288, 289, 326, 327, 330, 340, 341, 364, 449, and 473).
Docking with this wider binding pocket definition did not give additional
solutions.
At the end of the docking protocol, clustering based on ligand pairwise
rootmean square deviation (RMSD) criteria was performed, and the best-
scoring structure of the best-scoring cluster was taken as the best solution.
The clustering distance cutoff was reduced from the default 7.5-Å cutoff
for protein-protein complexes to 1.75 Å, which is more suitable for pro-
tein-ligand complexes.
The interactions between decanoic acid and PPAR were analyzed by
submitting the X-ray crystal structure 3U9Q to the HADDOCK refine-
ment server (32), which only performs a gentle refinement in explicit
solvent and returns statistics similar to those of a full docking run.
Microarray data accession numbers. The microarray data were sub-
mitted to Gene Expression Omnibus under accession no. GSE40706 and
GSE43065.
RESULTS
ANGPTL4 production is stimulated by short-chain fatty acids.
One set of molecules that maymediate the effect of microbiota on
ANGPTL4 expression in the colon are the short-chain fatty acids
(SCFA) acetate, propionate, and butyrate. To estimate the con-
centration of fatty acids to be used for in vitro experiments, we
determined the total SCFA concentration in the lumenof different
parts of the gastrointestinal (GI) tract of mice fed a low-fat diet
(Fig. 1A). Total SCFA concentration varied from	10 mM in the
proximal small intestine to 
40 mM in the cecum. In the colon
FIG 1 Physiological concentrations of SCFA stimulate ANGPTL4 mRNA and protein secretion in colon adenocarcinoma cells. (A) Total SCFA concentration
in different sections of the intestine ofmice fed a low-fat diet. Errors bars represent SEM. (B)Concentration of individual SCFA in colon ofmice fed a low-fat diet.
Errors bars represent SEM. (C) ANGPTL4 concentration in medium of T84 and HT29 cells treated with SCFA for 24 h at the indicated concentrations. (D)
ANGPTL4 mRNA in T84 and HT29 cells treated with SCFA for 24 h at the indicated concentrations. (E) Time course of induction of ANGPTL4 mRNA in T84
cells by butyrate (1 mM). (F) Inhibitory effect of -amanitin (10 g/ml) on induction of ANGPTL4 secretion by 1 mM butyrate in T84 cells. (G) Effect of rectal
infusion of propionate onAngptl4mRNA in epithelial scrapings ofmouse colon. Errors bars represent SEM. (H) Time course of regulation of ANGPTL4 protein
in medium of T84 and HT29 cells by trichostatin A (100 nM) and butyrate (8 mM). (I) Stimulatory effect of trichostatin A (100 nM) on LGALS1 mRNA in T84
cells. Error bars represent standard deviations (SD) except where indicated otherwise. An asterisk indicates a result significantly different from that of the control
according to Student’s t test (P	 0.05).
Alex et al.
1306 mcb.asm.org Molecular and Cellular Biology
the highest concentrations were found for acetate, followed by
propionate and butyrate (Fig. 1B). In the literature, even higher
concentrations have been reported that exceed 100 mM (35).
Based on these data, we used low- to medium-millimolar SCFA
concentrations.
To study regulation of ANGPTL4 production in colonocytes,
we used the human colonic adenocarcinoma cell lines T84 and
HT29. Remarkably, all SCFA significantly increased ANGPTL4
secretion by T84 and HT29 cells (Fig. 1C). The strongest effects
were observed for butyrate, followed by propionate and acetate.
Increased ANGPTL4 secretion was mirrored by a pronounced in-
crease in ANGPTL4mRNA (Fig. 1D), suggesting SCFA stimulate
ANGPTL4 transcription, which was further supported by the
rapid time course of induction of ANGPTL4 mRNA by butyrate
(Fig. 1E). Furthermore, induction of ANGPTL4 secretion by bu-
tyrate was almost completely abolished by -amanitin, an inhib-
itor of RNA polymerase II (Fig. 1F). In support of in vivo regula-
tion of Angptl4 gene expression by SCFA, rectal infusion of
propionate significantly increased Angptl4 mRNA expression in
mouse colon (Fig. 1G).
Butyrate and, to a lesser extent, propionate are able to inhibit
histone deacetylase (HDAC) activity, while acetate is ineffective
(36, 37). To study the impact of HDAC inhibition on ANGPTL4
secretion, we treated T84 and HT29 cells with the specific HDAC
inhibitor trichostatin A, which, similar to butyrate, inhibits class I
and class II HDACs. Unlike butyrate, trichostatin A had no effect
on ANGPTL4 secretion (Fig. 1H), indicating that the stimulatory
effect of butyrate on ANGPTL4 is likely independent of HDAC
inhibition. The effectiveness of trichostatin A was demonstrated
by the marked induction of the LGALS1 gene (Fig. 1I).
PPAR mediates induction of ANGPTL4 by SCFA. Because
the medium-chain fatty acid (MCFA) decanoic acid was recently
shown to be a direct ligand of PPAR and ANGPTL4 is a sensitive
target of PPAR in colonocytes (31, 38), we hypothesized that
butyrate upregulates ANGPTL4 expression in colonocytes by ac-
tivating PPAR. To test the responsiveness of ANGPTL4 to PPAR
activation in T84 and HT29 cells, the cells were treated with syn-
thetic agonists for PPAR, PPAR, and PPAR. The PPAR ago-
nist rosiglitazone was the most potent inducer of ANGPTL4 pro-
tein secretion (Fig. 2A) and mRNA (Fig. 2B) in both cell types,
followed by the PPAR agonist GW501516 and the PPAR ago-
nist Wy14643. These results are consistent with the high expres-
sion of PPARG mRNA in T84 cells (Fig. 2C, top) and, to a lesser
extent, in HT29 cells (Fig. 2C, lower) and the corresponding pro-
FIG 2 PPAR potently stimulates ANGPTL4 in colon adenocarcinoma cells. Synthetic agonists for PPAR (Wy14643 [WY]; 5M), PPAR (GW501516 [GW];
1 M), and PPAR (rosiglitazone [Rosi]; 1 M) stimulate ANGPTL4 secretion (A) and mRNA expression (B) in T84 and HT29 cells. Cntl, control. (C)
Amplification curve of PPAR, PPAR, and PPARmRNA as determined by qPCR of T84 and HT29 cells. Sizes of amplicons varied less than 10%. (D) Time
course of induction of ANGPTL4 protein inmedium by rosiglitazone (1M). (E) Dose-dependent induction of ANGPTL4 protein inmedium by rosiglitazone.
Unless indicated otherwise, cells were treated for 24 h. Error bars represent SD. An asterisk indicates a result significantly different from that of the control
according to Student’s t test (P	 0.05).
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tein levels of the three PPARs in the two cell lines (39–43). Upon
incubation with rosiglitazone, a time- and dose-dependent in-
crease inANGPTL4 proteinwas observed in T84 cells (Fig. 2D and
E), indicating that ANGPTL4 production is highly sensitive to
PPAR activation. Accordingly, we considered PPAR as a possi-
ble candidate mediating induction of ANGPTL4 mRNA by bu-
tyrate.
To investigate whether the stimulatory effect of butyrate on
ANGPTL4 secretion occurs via PPAR, we used the PPAR an-
tagonist GW9662. Induction of ANGPTL4 secretion by butyrate
in T84 cells was strongly diminished by GW9662 (Fig. 3A), sug-
gesting that butyrate increases ANGPTL4 secretion mainly by ac-
tivating PPAR. Similarly, siRNA-mediated knockdown of
PPAR mRNA by about 60% led to a very significant 40% de-
crease in the butyrate-induced ANGPTL4 mRNA level (Fig. 3B)
and butyrate-induced ANGPTL4 protein secretion (Fig. 3C),
again suggesting that the effect of butyrate on ANGPTL4 is largely
mediated by PPAR. Stimulation of PPAR mRNA by butyrate
(Fig. 3B) likely reflects PPAR autoregulation. To further pursue
the role of PPAR in ANGPTL4 regulation by butyrate, we per-
formed chromatin immunoprecipitation to study binding of
PPAR to the ANGPTL4 gene. The results indicate that PPAR
occupies the PPAR binding site within intron 3 of the ANGPTL4
gene (Fig. 3D), which is known to mediate PPAR responsiveness
(44, 45). Occupancy was modestly induced by both butyrate and
rosiglitazone. Taken together, these data strongly suggest that in-
duction of ANGPTL4 by butyrate in T84 cells is mediated by
PPAR.
To investigate whether butyrate acts as a general inducer of
PPAR-dependent gene regulation, we performed microarray
analysis on T84 cells treated either with butyrate (1 and 8 mM) or
rosiglitazone. Remarkably, effects of butyrate on global gene ex-
pression were much more pronounced than those of rosiglita-
zone, which is likely linked to its property as a potent HDAC
inhibitor (Fig. 4A; also see Fig. S1 in the supplemental material).
Interestingly, more overlap was observed between 1 mM butyrate
and rosiglitazone than between 8 mM butyrate and rosiglitazone
(see Fig. S1). Cluster analysis identified clusters of genes induced
by rosiglitazone and butyrate (Fig. 4A). Genes in one cluster,
which, besidesANGPTL4, included PPAR targetsHMOX1,PDK4,
andUCP2 (46–48), were induced by 1 and 8 mM butyrate. Genes
in another cluster, which included other PPAR targets, including
AQP8 and PLIN2 (49, 50), were induced by 1 mM butyrate and
surprisingly were not induced or even suppressed by 8 mM bu-
tyrate. The role of PPAR in mediating the stimulatory effect of 1
mMbutyrate on expression of PLIN2 andUCP2, representing two
distinct clusters, was verified by siRNA (Fig. 4B).
The biphasic regulation of AQP8 and PLIN2 by butyrate but
not by propionate and acetate was confirmed by qPCR (Fig. 4C).
Such a biphasic regulation is possible only if a gene is regulated by
at least two distinct mechanisms: a stimulatory effect, presumably
via PPAR, which is already active at lower butyrate concentra-
tions, and a suppressive effect impacting a subset of PPAR targets
at higher butyrate concentrations. Overall, these data indicate that
SCFA acts as a general inducer of PPAR-dependent gene regula-
tion in T84 cells. However, especially at higher concentrations, the
main effects of SCFA in T84 cells are independent of PPAR.
SCFA function as PPAR agonists. To further study activa-
tion of PPAR by SCFA, we employed a stable PPAR reporter
assay. HeLa cells stably transfected with a fusion construct be-
tween the DNA binding domain of Gal4 and the ligand binding
domain of PPAR, PPAR, or PPAR were incubated with in-
FIG 3 Induction of ANGPTL4 by butyrate is mediated by PPAR. (A) Inhibitory effect of PPAR antagonist GW9662 (5 M) on induction of ANGPTL4
secretion in medium by rosiglitazone (10 nM) and butyrate (1 mM) in T84 cells. Effect of siRNA-mediated PPAR knockdown (B, left) in T84 cells on
butyrate-induced upregulation of ANGPTL4mRNA (B, right) and ANGPTL4 protein in medium (C). (D) PPARChIP-qPCR on selected loci in T84 cells
treated with butyrate (8 mM) or rosiglitazone (1 M) for 24 h. Bars represent the mean recovery plus ranges from two independent experiments. Error
bars represent SD except when indicated otherwise. An asterisk indicates a significantly different result from that of the control according to Student’s t
test (P 	 0.05).
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creasing concentrations of SCFA. Remarkably, PPAR was
strongly activated by butyrate and, to a lesser extent, by propi-
onate (Fig. 5A). In contrast, PPAR and PPAR were not acti-
vated by any of the SCFA, even at higher concentrations.
To corroborate activation of PPAR by SCFA, we performed
an alternative reporter assay in U2OS cells stably transfected with
a human PPAR expression construct and a PPRE-luciferase re-
porter construct. Similar to the results described above, propi-
onate, but especially butyrate,markedly activated PPAR reporter
activity, while acetate had minimal effect (Fig. 5B). The threshold
for stimulating reporter activity was 0.5 mM for butyrate and 10
nM for rosiglitazone, indicating that butyrate has relatively weak
PPAR agonist activity.
To explore the possibility that SCFA serve as direct PPAR
FIG 4 Global effects of butyrate inT84 cells. T84 cells were treatedwith rosiglitazone (1M)or butyrate (1 and 8mM) for 24 h and subjected toAffymetrixmicroarray
analysis. (A)Hierarchical clustering based on Pearson’s correlationwith average linkage. (B) Effect of siRNA-mediated PPAR knockdown in T84 cells on induction of
PLIN2 and UCP2 mRNA by butyrate. AQP8 mRNA (C) and PLIN2 mRNA (D) levels were determined in T84 cells treated with SCFA for 24 h at the indicated
concentrations. Error bars represent SD. An asterisk indicates a result significantly different from that of the control according to Student’s t test (P	 0.05).
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FIG 5 SCFA are agonists of PPAR. (A) Stable GAL4-PPAR chimera reporter assay showing activation of PPAR but not PPAR and PPAR by SCFA at
concentrations of1 mM. The dotted lines represent the levels of luciferase activity reached upon incubation with synthetic PPAR agonists. Cells were treated
for 24 h. Error bars represent SD. (B) Stable PPAR reporter assay showing activation of PPAR by SCFA at concentrations of500 M. Cells were treated for
24 h. Note the different x axis for rosiglitazone and the SCFA. Error bars represent SD. (C) A nuclear receptor PamChip assay was used tomeasure the interaction
between PPAR and immobilized peptides corresponding to specific coregulator-nuclear receptor binding regions in the presence and absence of rosiglitazone
(1 M), butyrate (40 mM), or acetate (40 mM). Representative images are shown. (D) Quantitation of the PamChip assay results for rosiglitazone and butyrate
compared to the control. Arrows point to the same peptides as those described for panel C.
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agonists, we used nuclear receptor PamChip arrays. In this system,
the interaction between soluble nuclear receptors and 53 immo-
bilized peptides corresponding to specific coregulator-nuclear re-
ceptor binding regions is studied. Using this system for PPAR,
we have previously generated ligand-specific coregulator interac-
tion profiles (25). Both rosiglitazone and butyrate promoted the
interaction between PPAR and numerous coactivator peptides
(e.g., CBP) (Fig. 5C). However, in contrast to rosiglitazone, bu-
tyrate did not relieve the interaction between PPAR and the
NCoR1 and NCoR2 corepressor peptides. Consistent with the
PPAR reporter data, acetate had little effect. Quantitative analy-
sis of the PamChip arrays is presented in Fig. 5D. These data sug-
gest that butyrate functions as a selective PPARmodulator (SP-
PARM) (51).
Modeling of butyrate bound to PPAR. To find support for
SCFA behaving as selective PPAR modulators, we performed
FIG 6 Modeling of butyrate into the PPAR binding pocket. (A) The model reveals the complex between butyrate and PPAR with the best HADDOCK score
(butyrate is shown as cyan sticks), overlaid with the crystal structure of the decanoic acid complex with PPAR (3U9Q, a decanoic acid, is shown as green sticks)
by aligning the protein backbone atoms of the two structures (ribbon displayed for the HADDOCKmodel). The displayed protein side chains are shown as thin
cyan or green sticks and the side chains making contacts with the docked butyrate or decanoic acid, respectively. Hydrogen bond contacts between the butyrate
and the protein are shown as yellow dashed lines. (B) Comparison of the binding location for coactivator peptide PGC-1 (blue ribbon) bound to PPAR
(HADDOCK model of the PPAR-butyrate complex, left) with the binding site for the SMRT corepressor peptide (purple ribbon) binding to PPAR (1KKQ;
right) (69). In both structures, the C-terminal portion of the PPARmolecule that forms helix AF-2 is colored pink for comparison. The structures were aligned
using the backbone atoms of the receptors.
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structural modeling of the binding of butyrate to PPAR using
HADDOCK (30, 32) (Fig. 6A). Docking of butyrate into PPAR
resulted in three different clusters of solutions, each showing bu-
tyrate bound in the ligand-binding pocket of the protein. The best
cluster in terms ofHADDOCK score was also the largest one (179/
200 calculated structures) (Table 2) and contained the best scoring
models. It reveals a binding mode very similar to that of decanoic
acid within the crystal structure of PPAR (3U9Q) (31). Specifi-
cally, the average RMSD between the butyrate and decanoic acid
common atoms upon aligning the backbone atoms of the PPAR
(ligand RMSD)was 1.55 0.29 Å for the best four clustermembers.
The remaining clusters have less favorable interaction energy.
Interactions between butyrate and PPAR are dominated by
electrostatic interactions and hydrogen bonds between the car-
boxylate group and several hydrogen bond-donating protein side
chains, which are very similar to those found in the structure with
decanoic acid (Fig. 6A). In the latter can be found hydrogen bonds
to four different side chains near the carboxylate group, namely,
His323 HE2, Ser289 OG, His449 HE2, and Tyr473 OH. The top
four structures of the best cluster (in terms of HADDOCK score)
reveal specific hydrogen bonds from the butyrate oxygens to
His323, Tyr473, and His449. The hydrogen bond to Ser289 is
neverobserved,while in twoof the structuresa fourthhydrogenbond
ismade toTyr327OH.The average buried surface area (BSA) for the
best four docking solutions is 286  14 Å2, and the average
HADDOCK score for the best four structures is7 3. In compar-
ison, the buried surface area andHADDOCKscore calculated for the
decanoic acid-PPAR structure are 478 Å2 and22.1, respectively.
We next explored the possible influence of butyrate on coacti-
vator and corepressor binding (Fig. 6B). Fortunately, the structure
of PPAR with decanoic acid also contained a bound PGC1 co-
activator peptide, allowing us tomodel butyrate dockedwithin the
crystal structure of PPAR complexed with the PGC-1 peptide.
However, no structures were available for corepressor (peptides)
binding to PPAR, which limited us to the crystal structure of
PPAR complexed with an antagonist and the SMRT corepressor
peptide (1KKQ). As shown in Fig. 6B, the binding sites for the
coactivator (left, shown in blue) and corepressor (right, shown in
purple) peptides occupy structurally analogous positions on
PPAR andPPAR and are likely to bemutually exclusive binding
events. The C-terminal AF2 helix of PPAR (shown in pink)
forms part of the binding site for the coactivator peptide PGC-1,
and stabilization of this helix is known to promote binding of
coactivator peptides (31). As can be seen from the structural com-
parison, the AF2 helix of PPAR also occludes part of the struc-
turally analogous binding site for the corepressor peptide binding
to PPAR. The butyrate molecule in the HADDOCK model
makes several contacts with the AF2 helix (such as the hydrogen
bond to Tyr473OH) that are very similar to the contacts that were
observed between decanoic acid and the AF2 helix in the X-ray
crystal structure of the decanoic acid-PPAR complex (3U9Q),
which is consistent with our finding using a coactivator peptide
binding assay that butyrate can promote at least partial agonismof
the PPAR receptor but does not promote dissociation of core-
pressor peptides.
SCFA do not induce PPAR-mediated adipogenesis. Given
that SCFA can activate PPAR-mediated transcription in reporter
assays but only partially overlap a full PPAR agonist in their
coregulator binding profile, SCFA may not display the same ca-
pacity as full agonists in cell-based assays. Since PPAR is a critical
regulator of adipogenesis and mediates stimulation of adipogen-
esis by rosiglitazone, we subsequently used stimulation of 3T3-L1
adipogenesis as an in vitro readout for PPAR activation by SCFA.
It has been shown that NCoR1 represses 3T3-L1 adipogenesis
and that dismissal of NCoR1 is essential for induction of adi-
pogenesis by PPAR agonists (52, 53). Since SCFA/butyrate
did not release the association between NCoR1 and PPAR as
observed using the PamChip array, it may be expected that
SCFA are unable to mimic the adipogenic effects of PPAR
agonists (29). Consistent with this notion and in contrast to
rosiglitazone, SCFA did not induce 3T3-L1 adipogenesis, as
revealed by oil red O staining (Fig. 7A) and gene expression
analysis of adipogenesis markers, which also represent PPAR
targets (Fig. 7B). In fact, at higher concentrations butyrate and
propionate suppressed adipogenesis (Fig. 7C). Furthermore, in
contrast to rosiglitazone, butyrate did not upregulate PPAR targets
indifferentiated3T3-L1adipocytes (Fig. 7D). Similarly, in contrast to
rosiglitazone, SCFA were unable to induce adipogenesis in the hu-
man SGBS adipocyte model, as revealed by lack of induction of adi-
pogenesis markers (Fig. 7E). Together with the data from colon cell
lines and PamChip arrays, these data support the classification of
SCFA as selective PPARmodulators.
Consumption of inulin leads to PPAR activation in mouse
colon. To find support for activation of PPAR by SCFA in vivo,
we studied the effect of dietary fiber on PPAR activation in mouse
colon. To that end, C57BL/6 mice were fed either a control diet
containing no soluble fiber or the same diet containing 10% inulin
for 10 days. Inulin feeding markedly increased concentrations of
acetate and propionate in the colon, which reached significance
for propionate (Fig. 8A). To study the effect of inulin on PPAR
target gene expression, colons were subjected to microarray anal-
ysis followed by gene set enrichment analysis. Remarkably, the
most significantly induced gene set was PPAR targets (false dis-
covery rate q-value, 0; normalized enrichment score, 2.44) (54). It
should be noted that PPAR target genes cannot be separated ac-
cording to PPAR isotype. Representation of the individual expres-
sion changes of themost highly ranked genes within PPAR targets
in a heatmap reveals the pronounced and consistent induction of
numerous PPAR targets by inulin (Fig. 8B). These data suggest
that gut microbial activity and resultant formation of SCFA leads
to activation of PPARs.
TABLE 2 Characteristics of PPAR complexes with fatty acidsa
Complex BSA (Å2)
HADDOCK
scoreb (AU)
Ligand
RMSDc (Å)
Size of
clusterd
3U9Q 478 6 22.1 2.9 0.0 NA
Cluster 1-butyrate 286 14 7 3 1.55 0.29 179
Cluster 2-butyrate 280 6 0.1 4 4.70 0.77 13
Cluster 3-butyrate 275 6 4.6 4 1.99 0.13 6
a Averages and standard deviations calculated from the best four members (in terms of
HADDOCK score) of a set of structures are reported. 3U9Q is the HADDOCK-refined
crystal structures of the PPAR-decanoic acid complex, while the other three clusters
were obtained by HADDOCK modeling of the butyrate-PPAR complex. NA, not
applicable.
b HADDOCK score as defined in Materials and Methods.
c Positional RMSD of the ligand atoms calculated after superimposition of the protein
backbone atoms.
4 Number of calculated structures (out of 200 total) that were clustered together.
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FIG 7 Butyrate and propionate inhibit 3T3-L1 adipogenesis. (A) Oil red O staining of 3T3-L1 adipocytes at day 10 treated with SCFA (8 mM) from day
0. The mix contained 2.67 mM of each of the SCFA. (B) Expression of differentiation markers and PPAR targets was determined by qPCR at day 4. (C)
Concentration-dependent effect of butyrate on 3T3-L1 differentiation when added at day 0, as determined by expression of differentiation markers at day
4. (D) Effect of SCFA (8 mM) and rosiglitazone (1 M) on expression of PPAR targets in fully differentiated 3T3-L1 adipocytes. Cells were treated for
24 h. (E) Effect of SCFA (8 mM) and rosiglitazone (1 M) added on day 1 on human SGBS adipocyte differentiation and expression of adipogenesis
marker genes at day 15. Error bars represent SD. An asterisk indicates a result significantly different from that of the control according to Student’s t test
(P 	 0.05).
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DISCUSSION
Here, we explored the mechanisms involved in regulation of
ANGPTL4 synthesis in human colon. The two major findings are
(i) ANGPTL4 synthesis is highly stimulated by SCFA and (ii)
SCFA transactivate and bind to PPAR, likely by serving as selec-
tive PPAR modulators. Overall, the data indicate that SCFA in-
duce ANGPTL4mRNA expression and protein secretion in colon
cells by activating PPAR. Butyrate was the strongest activator
followed by propionate, whereas acetate only weakly stimulated
PPAR and ANGPTL4.
Butyrate is a potent histone deacetylase inhibitor, which likely
accounts for most of the observed effects of butyrate in colon
adenocarcinoma cells as revealed by microarray. Indeed, a far larger
number of genes was regulated by butyrate than by rosiglitazone,
suggesting that PPAR activation is quantitatively a relatively minor
pathway in gene regulation by SCFA, at least in T84 cells.
Two previous studies have hinted at potential activation of
PPAR by butyrate (55, 56), yet the concept has largely eluded
recognition in the field. In contrast, long-chain (unsaturated)
fatty acids (LCFA) are well-known activators of PPAR (57). They
activate PPAR at concentrations in the low- to medium-micro-
molar range and thus serve as high-affinity agonists of PPAR. In
contrast, concentrations of SCFA needed to activate PPAR are in
the high-micromolar to low-millimolar range. Due to the low
affinity, the in vivo relevance of PPAR activation by SCFA is likely
insignificant in most human tissues, including adipose tissue.
However, the situation is different in the GI tract and in liver (58).
Indeed, SCFA concentrations approaching or even exceeding 100
mM have been reported in human colon and cecum (59). In
mouse intestine, we measured total SCFA concentrations of
around 40 mM, which would result in substantial activation of
PPAR. Accordingly, we believe that activation of PPAR by
SCFA is physiologically meaningful only in human cecum and
colon and perhaps in liver.
Interestingly, medium-chain fatty acids (MCFA; C8 to C10)
were recently shown to act as modulators of PPAR (31). Similar
to the data reported here for SCFA, the MCFA decanoic acid
bound and (trans)activated PPAR, and contrary to synthetic
PPAR agonists and LCFA, decanoic acid inhibited adipogenesis.
Furthermore, it was shown that the hydrocarbon tail of decanoic
acid occupies a completely different pocket than the tail of LCFA
or rosiglitazone. Remarkably, even though no specific orienta-
tional or positional restraints were used to guide the binding of
butyrate in the large PPAR binding site, the most favorable so-
lution to the docking was very similar to that of decanoic acid. In
general, the best solutions of the docking protocol displayed high-
quality interactions with the PPAR receptor, with a slightly dif-
ferent orientation of the butyrate carboxylic acid group in the
binding site compared to decanoic acid. The model shows that
butyrate is stabilized in the binding site by interactions with pro-
tein side chains. Since the buried surface area and interaction en-
ergy with the receptor are less than those for decanoic acid, the
affinity of the complex with butyrate is predicted to be weaker
than that with decanoic acid.
PPAR has an antineoplastic effect in many different tumor
types, yet its role in colorectal tumors remains controversial (60).
In contrast, the anti-inflammatory effect of PPAR in the colon is
well recognized (61). PPAR ligands were shown to suppress in-
flammatory gene expression in colonic cell lines by suppressing
NF-B and reduce inflammation in a mouse model of inflamma-
tory bowel disease (62, 63). In addition, PPAR in colonic epithe-
lial cells was shown to protect against experimental inflammatory
bowel disease (49). Similarly, SCFA, especially butyrate, seem to
have broad anti-inflammatory properties by altering immune cell
migration, adhesion, and cytokine expression and by affecting cell
proliferation and apoptosis (64). Accordingly, it can be hypothe-
sized that the anti-inflammatory properties of SCFA in the colon
are at least partially conveyed by PPAR (65).
Previously, ANGPTL4 expression in the human colon cell line
HT29 was found to be stimulated by heat-stable factors secreted
by the probiotic bacteria Lactobacillus strain F19 in a PPAR- and
PPAR-dependent manner (20). Based on data presented here, it
seems highly plausible that the secreted factors represent SCFA.
Thus, probiotic and resident microbiota may be able to influence
ANGPTL4 production via production of SCFA and subsequent
activation of PPAR. Backhed reported that colonization of the
gut of germ-free mice with microbiota reduces Angptl4 expres-
sion in mouse intestine (2). Inasmuch as SCFA stimulate
ANGPTL4 expression, the suppressive effect of colonization on
ANGPTL4must be mediated by amechanism other than SCFA.
It has been suggested that alterations in intestinal Angptl4 ex-
pression influence adipose LPL activity and thereby impact adi-
pose mass (2). SCFA may thus inhibit fat storage by stimulating
release of ANGPTL4. Whether ANGPTL4 also has a functional
role in the intestine is unclear. Since the intestine does not express
LPL, the local role of ANGPTL4 in intestine must extend beyond
FIG 8 Inulin feeding activates PPAR in colon. Mice were fed a diet enriched
with inulin for 10 days. (A) Lumenal concentration of SCFA in the colon as
determined by gas chromatography. Error bars represent SEM. (B) Gene ex-
pression changes in colon illustrated by heat map of genes belonging to the
most significantly induced gene set, termed PPAR targets. SLR, signal log ratio.
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LPL inhibition. LPL inhibition is conferred exclusively by the N-
terminal domain of ANGPTL4, whereas the C-terminal fragment
of ANGPTL4 acts as a ligand for integrins to alter cellular signaling
(66–68).
In conclusion, we show that SCFA potently stimulate
ANGPTL4 production in human colon cell lines via PPAR. Our
data point to activation of PPARs as a novel mechanism of gene
regulation by SCFA in the colon, in addition to othermechanisms
of action of SCFA.
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